



5 July 2023
EMA/310145/2023
Human Medicines Division

Overview of (invented) names reviewed in June 2023 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 17-20 July 2023

	NRG meeting 14-15 Feb 2023		NRG meeting 26 Apr 2023		NRG meeting 26-27 Jun 2023		NRG meeting 18-19 Sep 2023		NRG meeting 14-15 Nov 2023		2023 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names*	52	51	62	31	85	32					199	114
Justification for retention of (invented) name **	0	7	0	4	2	5					2	16

*Includes invented names, INN+MAH/TM and re-use applications.

**In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



	NRG meeting 14-15 Feb 2023		NRG meeting 26 Apr 2023		NRG meeting 26-27 Jun 2023		NRG meeting 18-19 Sep 2023		NRG meeting 14-15 Nov 2023		2023 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Total number of objections raised	88	155	51	130	66	162					205	447
Similarity with other (invented) name	53	173	33	97	53	122					139	392
Conveys misleading therapeutic/pharmaceutical connotations	5	0	3	1	1	4					9	5
Misleading with respect to composition	0	0	0	0	0	0					0	0
Similarity with INN	8	17	5	4	4	8					17	29
Inclusion of INN stem	3	0	0	1	0	0					3	1
Unacceptable qualifiers	0	0	0	0	0	0					0	0
Conveys a promotional message	4	7	1	4	1	4					6	15
Appears offensive or has an inappropriate connotation	5	1	2	1	3	2					10	4
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0	0	0	0	0					0	0
Similarity between name of prodrug and related active substance	0	0	0	0	0	0					0	0
Others	10	2	5	12	7	10					22	24

See *Guideline on the [Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure \(EMA/CHMP/287710/2014\)](#)* for detailed explanations of criteria used.